English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose : To evaluate the genotoxicity of CSE1034, a novel antibiotic  adjuvant entity, using bacterial reverse mutation assay (Ames test) and in vitro chromosomal aberration test. Methods : Reverse mutation test was carried out using four strains of  Salmonella typhimurium (TA 98, TA100, TA1535 and TA1537) and one strain of E. coli [WP2 (uvrA)], while chromosomal aberration test was done with cultured Chinese hamster lung (CHL) cells. Reverse mutation test was carried out in a dose range of 0.0015 to 0.16 ig/plate in triplicate with and without S9 activation. Results : No significant increases in the number of revertants were observed at the dose levels where antibacterial effects were not noted. CSE1034 caused no increase in the number of chromosomal aberrants at dose levels of 0.34, 0.69, 1.37, 2.75 and 5.50 mg/ml in the absence and presence of metabolic activation. Conclusion : Based on the above observations, it can be concluded that CSE1034 has no mutagenic activity. Keywords : CSE1034, reverse mutation, antibiotic adjuvant entity, Chromosomal aberration, Mutagenic

Evaluation of Genotoxicity of CSE1034 by Ames and <i>In vitro</i> Chromosomal Aberration Tests